Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)

Ger­many deal with Cure­Vac and GSK primed for 80M mR­NA vac­cines a year

If there’s an­oth­er pan­dem­ic, the Ger­man gov­ern­ment is de­ter­mined not to be caught off-guard when it comes to man­u­fac­tur­ing vac­cines.

Cure­Vac and GSK have signed a deal to sup­ply Ger­many with mR­NA vac­cines for pan­dem­ic pre­pared­ness go­ing for­ward. Af­ter a set­up pe­ri­od that will last no longer than two years, the con­tract gives Ger­many’s gov­ern­ment ac­cess to the Cure­Vac man­u­fac­tur­ing ca­pac­i­ty un­til 2029.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.